G&S Research promotes Mike Bandick to SVP

Healthcare marketing research firm G&S Research promoted Mike Bandick to SVP. The move follows a company restructuring that put Bandick at the head of R&S Research's client solutions group.

George Grubb, principal of G&S Research, said in a statement that Bandick's leadership has been “instrumental in navigating the complex opportunities and recent economic contraction of the biopharmaceutical market space that we serve.”

Bandick joined R&S Research in 2006 as VP and business unit leader, and will remain a member of the company's executive committee. Prior to joining R&S Research, Bandick was senior director of marketing for Suros Surgical Systems, which was acquired by Hologic. Before that, Bandick worked in several capacities with Eli Lilly, and was most recently a global marketing director on Cymbalta, Lilly's antidepressant and pain treatment. He also worked on Zyprexa, Lilly's schizophrenia and bipolar drug. 
You must be a registered member of MMM to post a comment.

Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.

Email Newsletters